Biotech

April 26, 2016 08:30 ET | Source:Minerva Neurosciences, Inc. WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2016 …

| Source:Minerva Neurosciences, Inc.



WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2016 on Tuesday, May 3, 2016.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 74086869.  A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva’s proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which recently completed Phase IIa and Phase Ib clinical trials for insomnia and major depressive disorder (MDD), respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com.

Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

 

Related Articles
other press releases byMinerva Neurosciences, Inc.

 






MARKETS

Markets
TSX18444.22+2.38
TSXV594.13+11.54
DOW28725.51-500.10
S&P 5003585.62-54.85
NASD10575.62-161.89
ASX6555.00+93.00

COMMODITIES

Commodities
Gold1660.60-3.97
Silver19.03+0.13
Copper3.39-0.03
Palladium2172.79-32.21
Platinum864.79-5.21
Oil79.74-1.49
Heating Oil3.23-0.07
Natural Gas6.83-0.05

DOWNLOAD FREE REPORTS

×